skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
dHER2 Vaccine+AS15 Adjuvant (Code C84861)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: dHER2 Vaccine+AS15 Adjuvant

Definition: A cancer vaccine consisting of a truncated recombinant HER2/neu peptide (dHER2) combined with the immunoadjuvant AS15 with potential immunostimulatory and antineoplastic activities. Upon administration, dHER2+AS15 vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells that overexpress the HER2/neu protein, resulting in tumor cell lysis. The tumor-associated antigen (TAA) HER2/neu is often overexpressed by a variety of tumor cell types; dHER2 includes amino acids 1-645 or 1-653 of the extracellular domain (ECD) and an immunogenic carboxyl terminal autophosphorylation portion of the intracellular domain (ICD). AS15 is an adjuvant formulation that contains the adjuvant systems AS01B and AS07A; AS01 B is composed of liposomes containing 3D-MPL and QS21 and AS07A is composed of the synthetic oligodeoxynucleotide (ODN) Toll-like receptor-9 (TLR9) agonist CpG 7909.

Display Name: dHER2 Vaccine+AS15 Adjuvant

Label: dHER2 Vaccine+AS15 Adjuvant

NCI Thesaurus Code: C84861 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL412425  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
dHER2 Vaccine+AS15 Adjuvant

External Source Codes: 
PDQ Closed Trial Search ID 652800
PDQ Open Trial Search ID 652800 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C84861
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom